title: Angiotensin-converting enzyme inhibition in patients with coronary artery disease and preserved left ventricular function Ischemia Management with Accupril post-bypass graft via inhibition of angiotensin-converting enzyme (IMAGINE) compared with the other major trials in coronary artery disease.
abstract: It has been hypothesized that angiotensin-converting enzyme (ACE) inhibition, independent from its effect on ventricular function and blood pressure, could affect the atherosclerotic process and reduce the incidence of ischemic events and its complications. Several large clinical outcome trials were designed to test this hypothesis: QUIET, HOPE, EUROPA, PEACE, and IMAGINE. The results of the PEACE study were recently reported, leaving the IMAGINE study as the last chapter in our efforts to evaluate the role of ACE inhibition in coronary artery disease with preserved left ventricular function. In this report, we compare these studies with respect to their methodology and patient population and analyze the unique nature of the last ongoing study, IMAGINE. The reported studies show that patients with coronary artery disease who are at low-to-moderate or high risk should receive an ACE inhibitor if tolerated. However, when the absolute risk of a patient decreases, and intensive contemporary management is given, with good control of risk factors, the absolute and perhaps relative benefits of an ACE inhibitor decrease and their routine use in these patients may not be warranted. The role of ACE inhibition started early post-coronary artery bypass graft in patients with preserved left ventricular function, and intensive contemporary management remains to be determined and should get answered by the IMAGINE study. Moreover, the IMAGINE population is not only a lower risk population than those enrolled in HOPE or EUROPA, but also the risk for this population is bimodal in nature (early post-revascularization inflammation and thrombosis vs long-term atherosclerosis progression) and may provide further insight into underlying mechanisms.
authors.affiliation: Department of Cardiology and Clinical Pharmacology, University Medical Center Groningen, The Netherlands. w.h.van.gilst@med.rug.nl
authors.forename: Wiek H
authors.initials: WH
authors.lastname: van Gilst
authors.forename: J Wayne
authors.initials: JW
authors.lastname: Warnica
authors.forename: Richard
authors.initials: R
authors.lastname: Baillot
authors.forename: David
authors.initials: D
authors.lastname: Johnstone
authors.forename: Cristina-Dana
authors.initials: CD
authors.lastname: Calciu
authors.forename: Pierre
authors.initials: P
authors.lastname: Block
authors.forename: Martin G
authors.initials: MG
authors.lastname: Myers
authors.forename: Sidney
authors.initials: S
authors.lastname: Chocron
authors.forename: Jean-Lucien
authors.initials: JL
authors.lastname: Rouleau
mesh_terms: D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001026:Coronary Artery Bypass; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077583:Quinapril; D016032:Randomized Controlled Trials as Topic; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use*; D016277:Ventricular Function, Left
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D044005:Tetrahydroisoquinolines; D000077583:Quinapril